Furthermore, it has been reported that BC patients’ pCR after management with NAT involving anti-HER2 agents may be a surrogate marker for their prognosis, with those who achieved pCR exhibiting significantly better prognosis (11, 12). The gene discussed is ERBB2; the disease is breast cancer.